NASDAQ:AKBA Akebia Therapeutics (AKBA) Stock Price, News & Analysis $1.44 -0.04 (-2.70%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.41▼$1.5250-Day Range$0.86▼$1.4852-Week Range$0.78▼$2.48Volume1.14 million shsAverage Volume3.81 million shsMarket Capitalization$301.82 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Akebia Therapeutics alerts: Email Address Akebia Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside247.2% Upside$5.00 Price TargetShort InterestBearish8.90% of Shares Sold ShortDividend StrengthN/ASustainability-1.35Upright™ Environmental ScoreNews Sentiment0.51Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.28) to ($0.23) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.29 out of 5 starsMedical Sector348th out of 936 stocksPharmaceutical Preparations Industry162nd out of 436 stocks 3.5 Analyst's Opinion Consensus RatingAkebia Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAkebia Therapeutics has received no research coverage in the past 90 days.Read more about Akebia Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.90% of the outstanding shares of Akebia Therapeutics have been sold short.Short Interest Ratio / Days to CoverAkebia Therapeutics has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Akebia Therapeutics has recently increased by 42.33%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAkebia Therapeutics does not currently pay a dividend.Dividend GrowthAkebia Therapeutics does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAkebia Therapeutics has received a 55.61% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Various other types of medication (V)" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Akebia Therapeutics is -1.35. Previous Next 2.0 News and Social Media Coverage News SentimentAkebia Therapeutics has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Akebia Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for AKBA on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Akebia Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Akebia Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.10% of the stock of Akebia Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 33.92% of the stock of Akebia Therapeutics is held by institutions.Read more about Akebia Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Akebia Therapeutics are expected to grow in the coming year, from ($0.28) to ($0.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akebia Therapeutics is -6.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akebia Therapeutics is -6.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Akebia Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad American Hartford Gold GroupPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE About Akebia Therapeutics Stock (NASDAQ:AKBA)Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Read More AKBA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AKBA Stock News HeadlinesJuly 21, 2024 | finance.yahoo.comAKBA Aug 2024 0.500 call (AKBA240816C00000500)July 18, 2024 | americanbankingnews.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest UpdateJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 11, 2024 | prnewswire.comAkebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) TabletsJuly 1, 2024 | prnewswire.comAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 27, 2024 | prnewswire.comAkebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual ConferenceJune 24, 2024 | prnewswire.comAkebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business OfficerJune 3, 2024 | prnewswire.comAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 23, 2024 | prnewswire.comAkebia Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 14, 2024 | prnewswire.comAkebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor ConferenceMay 11, 2024 | finance.yahoo.comRevenue Downgrade: Here's What Analysts Forecast For Akebia Therapeutics, Inc. (NASDAQ:AKBA)May 10, 2024 | finance.yahoo.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comAkebia Therapeutics Reports Q1 2024 Financial Results: A Detailed OverviewMay 10, 2024 | finance.yahoo.comAkebia Therapeutics First Quarter 2024 Earnings: Misses ExpectationsMay 9, 2024 | seekingalpha.comAkebia Therapeutics, Inc. (AKBA) Q1 2024 Earnings Call TranscriptMay 9, 2024 | investorplace.comAKBA Stock Earnings: Akebia Therapeutics Misses EPS, Misses Revenue for Q1 2024May 9, 2024 | sfgate.comAkebia Therapeutics: Q1 Earnings SnapshotSee More Headlines Receive AKBA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AKBA CUSIPN/A CIK1517022 Webwww.akebia.com Phone(617) 871-2098Fax617-871-2099Employees430Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$6.00 Low Stock Price Target$4.00 Potential Upside/Downside+235.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,920,000.00 Net Margins-22.99% Pretax Margin-22.99% Return on EquityN/A Return on Assets-18.01% Debt Debt-to-Equity RatioN/A Current Ratio1.70 Quick Ratio1.31 Sales & Book Value Annual Sales$194.62 million Price / Sales1.60 Cash FlowN/A Price / Cash FlowN/A Book Value($0.16) per share Price / Book-9.31Miscellaneous Outstanding Shares209,600,000Free Float201,003,000Market Cap$312.30 million OptionableOptionable Beta0.77 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. John P. Butler MBA (Age 60)CEO, President, Interim Principal Financial Officer & Director Comp: $1.81MMr. Michel Dahan (Age 45)Senior VP & COO Comp: $1.02MMs. Nicole R. Hadas J.D. (Age 51)Senior VP, Chief Legal Officer & Secretary Comp: $933.3kDr. Steven Keith Burke M.D. (Age 63)Senior VP of Research & Development and Chief Medical Officer Comp: $937.39kMr. Richard C. Malabre (Age 63)Chief Accounting Officer Ms. Kimberly GarkoSenior VP & Chief Technical OfficerTracey VetterickVice President of Portfolio Strategy & Corporate AdministrationMercedes CarrascoSenior Director of Investor & Corporate CommunicationsMs. Meredith BowmanSenior VP & Chief People OfficerMs. Carolyn RucciSenior Vice President of Legal & General CounselMore ExecutivesKey CompetitorsUroGen PharmaNASDAQ:URGNPuma BiotechnologyNASDAQ:PBYIRAPT TherapeuticsNASDAQ:RAPTMarinus PharmaceuticalsNASDAQ:MRNSSpero TherapeuticsNASDAQ:SPROView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 585,789 shares on 7/26/2024Ownership: 0.288%Assenagon Asset Management S.A.Sold 578,836 shares on 7/18/2024Ownership: 0.101%SG Americas Securities LLCBought 33,144 shares on 7/12/2024Ownership: 0.016%Jacobs Levy Equity Management Inc.Sold 219,347 shares on 5/16/2024Ownership: 0.781%Torno Capital LLCBought 5,800 shares on 5/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions AKBA Stock Analysis - Frequently Asked Questions How have AKBA shares performed this year? Akebia Therapeutics' stock was trading at $1.24 on January 1st, 2024. Since then, AKBA shares have increased by 16.1% and is now trading at $1.44. View the best growth stocks for 2024 here. How were Akebia Therapeutics' earnings last quarter? Akebia Therapeutics, Inc. (NASDAQ:AKBA) announced its earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.09). The biopharmaceutical company had revenue of $32.61 million for the quarter, compared to the consensus estimate of $41.13 million. What is John Butler's approval rating as Akebia Therapeutics' CEO? 28 employees have rated Akebia Therapeutics Chief Executive Officer John Butler on Glassdoor.com. John Butler has an approval rating of 97% among the company's employees. This puts John Butler in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. Who are Akebia Therapeutics' major shareholders? Top institutional investors of Akebia Therapeutics include Bank of New York Mellon Corp (0.29%), Assenagon Asset Management S.A. (0.10%), SG Americas Securities LLC (0.02%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include John P Butler, Steven Keith Burke, Michel Dahan, Nicole R Hadas, David A Spellman and Violetta Cotreau. View institutional ownership trends. How do I buy shares of Akebia Therapeutics? Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Akebia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD) and Corbus Pharmaceuticals (CRBP). This page (NASDAQ:AKBA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akebia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
